APTAHEM
Aptahem's development portfolio consists of aptamers , so-called synthetic (engineered) nucleic acid polymers. An aptamer consists of either single-stranded DNA or RNA (ssDNA or ssRNA). These molecules can bind specifically to already selected targets, including proteins and peptides with high affinity and specificity. Unlike antibodies, some aptamers exhibit stereoselectivity. Aptahem develops aptamer-based drugs for the treatment of life-threatening conditions where coagulation and inflammation interact in the disease process. Apta-1, the company's leading drug candidate, is an emergency medicine that is developed with the aim of stopping the organ and tissue damage that leads to the very high mortality rate for, among other things, sepsis patients.
APTAHEM
Industry:
Biotechnology
Founded:
2014-01-01
Address:
Malmö, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.aptahem.com
Total Employee:
1+
Status:
Active
Technology used in webpage:
Euro Danish Server Location
Similar Organizations
Aptarion biotech
Aptarion biotech is a developer Biostable L-Aptamers for the treatment Of Life-Threatening diseases And for Biosensors.
F2G
F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
Vetigenics
Vetigenics discovers and develops antibody-based immunotherapies to treat cancer and chronic diseases in companion animals
Current Employees Featured
Founder
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-31 | Aptahem appoints CMC Director |
Official Site Inspections
http://www.aptahem.com Semrush global rank: 11.53 M Semrush visits lastest month: 156
- Host name: webcluster2.webpod16-cph3.one.com
- IP address: 46.30.215.119
- Location: Copenhagen Denmark
- Latitude: 55.6786
- Longitude: 12.5589
- Timezone: Europe/Copenhagen
- Postal: 1052
More informations about "Aptahem"
Aptahem - Crunchbase Company Profile & Funding
Aptahem develops aptamer-based drugs for the treatment of life-threatening conditions where coagulation and inflammation interact in the disease process. Apta-1, the company's leading …See details»
Team - Aptahem
4 days ago Hos Aptahem kommer Suzanne att leda och koordinera planerings- och förberedelsearbetet för att ta Apta-1 till klinisk fas I. Innehav i bolaget: Suzanne Kilany äger 6 …See details»
Aptahem » Valberedningens förslag till styrelse och …
Mar 6, 2025 Aptahem AB Mikael Lindstam, VD Tel: 0766-33 36 99 Epost: [email protected]. Kort om Aptahem Aptahem AB (APTA) är ett bioteknikbolag i klinisk fas som utvecklar RNA …See details»
Valberedningens förslag till styrelse och styrelseordförande inför ...
Mar 6, 2025 Valberedningens samtliga förslag kommer att presenteras i kallelsen till årsstämman och förslagen samt motivering till förslaget om styrelsens sammansättning …See details»
Aptahem | VentureRadar
Aptahem AB is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation …See details»
Aptahem’s founder is back – now as …
3 July, 2021On September 25, Bert Junno was elected Chairman of the Board of the biotech company Aptahem. As a founder of several companies in the industry, including Aptahem in 2014, …See details»
Maria Ekblad - COO @ Aptahem - Crunchbase Person Profile
CB Rank (Person) 1,831,852 Primary Job TitleSee details»
Aptahem AB (publ) genomför en företrädesemission om cirka 28 …
May 3, 2023 Aptahem AB Mikael Lindstam, VD Tel: 0766-33 36 99 Epost: [email protected]. Denna information är sådan information som Aptahem AB är skyldigt att offentliggöra enligt …See details»
Aptahem enters agreement with international clinical CRO for …
May 17, 2022 Aptahem (publ) announces today that the company has signed an agreement with the clinical contract research organization (CRO) The Centre for Human Drug Researc ...See details»
Aptahem » Portfolio & Pipeline
Mar 13, 2025 Aptahem welcomes collaborations with academic groups around the world where their RNA-based therpeutical candidates can be studied in conditions including coagulation, …See details»
Aptahem proposes new election of Mikael Gustavsson to the Board
Mar 6, 2025 The Nomination Committee of the research company Aptahem proposes the election of Mikael Gustavsson as a new Board member for the 2025 Annual General Meeting. …See details»
Aptahem - Cision News
Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination …See details»
Aptahem receives patent approval in South Korea
Feb 14, 2025 The research company Aptahem has received a Notice of Patent Grant in South Korea for a patent application entitled A nucleic acid molecule with anti-inflammatory and anti …See details»
Aptahem finalizes Part 1a of the FIH study for its lead candidate …
Nov 9, 2023 Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today the finalization of FIH …See details»
Aptahem » Aptahems företrädesemission är registrerad och …
Jul 6, 2023 Aptahem AB Mikael Lindstam, VD Tel: 0766-33 36 99 Epost: [email protected]. Kort om Aptahem Aptahem AB (APTA) är ett bioteknikbolag i klinisk fas som utvecklar RNA …See details»
Teckningsperioden i Aptahems företrädesemission av units
Idag, den 15 januari 2024, inleds teckningsperioden i Aptahem AB:s (”Aptahem” eller ”Bolaget”) företrädesemission av units bestående av aktier och teckningsoptioner serie TO8 med …See details»
Aptahem (APTA) aksje - Nordnet
Kjøp Aptahem (APTA) aksjen. Hos Nordnet kan du handle fra 1 kr i kurtasje. Klikk her for å følge aksjekursen i realtid. Innstillinger for informasjonskapsler. Vi bruker informasjonskapsler på vår …See details»
Aptahem » Investerare
Mar 13, 2025 Aptahem beslutar om en partiellt garanterad företrädesemission av aktier om cirka 22,7 MSEK och upptar brygglån; 2 sep, 2024 Aptahem kommenterar intressanta data efter …See details»
Government of Canada announces the organization to establish …
2 days ago Today, the Honourable Kamal Khera, Minister of Health, announced over $6.3 million in funding over five years for the Sinneave Family Foundation to establish and lead the new …See details»
Aptahem » Historisk överblick
Mar 13, 2025 Aptahem grundades baserat på det nya förslaget för kommersiell terapeutisk användning av aptamererna som studerats och presenterats av dr Luiza Jedlina. 1996 De två …See details»